In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).

The study was amended and now includes patients with ocular surface inflammation.

In this prospective, single-centre, double blind (within each cohort), placebo controlled, randomised study, safety and tolerability of PP-001 eye drops is assessed in healthy, adult volunteers (cohorts 1-3) and in patients with ocular surface inflammation (cohort 4). PP-001 is a novel small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with anti-inflammatory properties.

Inclusion Criteria (excerpt):

Cohorts 1-3:

• male or female healthy volunteers 18 - 64 years of age
• good general state of health and participants must not have a diagnosis of any eye disease that could effect the pharmacokinetics of PP-001

Cohort 4:

• male or female subjects 18-64 years of age with ocular surface inflammation in both eyes
• ocular surface inflammation as defined per protocol
• good general state of health

Exclusion Criteria (excerpt):

Cohorts 1-4:

• participation in other clinical trials within 30 days prior to dosing start (ocular and non-ocular clinical trials)
• pregnant or nursing patients
• regular use of any ocular agents within 60 days prior to start dosing